Angelini Pharma invests in bespoke fund

Monday 2 August 2021
Country

Italy

The Italian healthcare group, Angelini Pharma, has become the sole institutional investor in a new venture fund that will provide capital to promising neuroscience companies in North America. The fund will be managed by Lumira Ventures of Canada and is called Angelini Lumira Biosciences Fund (ALBF). Angelini will commit $35 million to the fund in addition to investing $5 million in Lumira Ventures IV, a separate fund.